scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution

Abstract

Background:

Adeno-associated virus (AAV)-mediated gene therapies are rapidly advancing to the clinic, and AAV engineering has resulted in vectors with increased ability to deliver therapeutic genes. Although the choice of vector is critical, quantitative comparison of AAVs, especially in large animals, remains challenging.

Methods:

Here, we developed an efficient single-cell AAV engineering pipeline (scAAVengr) to simultaneously quantify and rank efficiency of competing AAV vectors across all cell types in the same animal.

Results:

To demonstrate proof-of-concept for the scAAVengr workflow, we quantified - with cell-type resolution - the abilities of naturally occurring and newly engineered AAVs to mediate gene expression in primate retina following intravitreal injection. A top performing variant identified using this pipeline, K912, was used to deliver SaCas9 and edit the rhodopsin gene in macaque retina, resulting in editing efficiency similar to infection rates detected by the scAAVengr workflow. scAAVengr was then used to identify top-performing AAV variants in mouse brain, heart and liver following systemic injection.

Conclusions:

These results validate scAAVengr as a powerful method for development of AAV vectors.

Funding:

This work was supported by funding from the Ford Foundation, NEI/NIH, Research to Prevent Blindness, Foundation Fighting Blindness, UPMC Immune Transplant and Therapy Center, and the Van Sloun fund for canine genetic research.

Data availability

Data, including count matrix files, raw fastq files as well as AAV/cell barcode tables generated from read quantification, have been uploaded to GEO under accession code GSE161645.

The following data sets were generated

Article and author information

Author details

  1. Bilge E Öztürk

    Ophthalmology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5117-077X
  2. Molly E Johnson

    Ophthalmology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  3. Michael Kleyman

    Computational Biology, Carnegie Mellon University, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  4. Serhan Turunç

    Ophthalmology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  5. Jing He

    Neurobiology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  6. Sara Jabalameli

    Ophthalmology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  7. Zhouhuan Xi

    Ophthalmology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  8. Meike Visel

    Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, United States
    Competing interests
    Meike Visel, MV is an inventor on AAV capsid variants (US patent IDs: 10,214,785, 10,745,453). MV has also received royalty payments from UC Berkeley. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5033-3730
  9. Valérie L Dufour

    Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  10. Simone Iwabe

    Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  11. Felipe Pompeo Marinho

    Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  12. Gustavo D Aguirre

    Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  13. José-Alain Sahel

    Neurobiology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    José-Alain Sahel, JAS has served as a consultant (with no consulting fee) for Pixium Vision, GenSight Biologics and SparingVision. Personal financial interests: Pixium Vision, GenSight Biologics, Prophesee and Chronolife, SparingVision, SHARPEYE, Vegavect, Newsight Therapeutics. The author has no other competing interests to declare..
  14. David V Schaffer

    Chemical Engineering, University of California, Berkeley, Berkeley, United States
    Competing interests
    David V Schaffer, DS is named as an inventor on patent applications on AAV capsid variants (U.S. Patent Applications No. 16/315,032, 16/486,681). DS is also a co-founder of 4D Molecular Therapeutics, and DS performs consultancy and owns stock options in this company. The author has no other competing interests to declare..
  15. Andreas R Pfenning

    Computational Biology, Carnegie Mellon University, Pittsburgh, United States
    Competing interests
    Andreas R Pfenning, AP has received an honorarium from the University of Rhode Island, and has applied for patents on specific Nuclear-Anchored Independent Labeling System (PCT/US2020/038520 and PCT/US2020/038528). The author has no other competing interests to declare..
  16. John G Flannery

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    John G Flannery, JGF is an inventor on patent application on AAV capsid variants (U.S. Patent Application No. 16/315,032, 16/486,681). The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0720-8897
  17. William A Beltran

    Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    William A Beltran, WAB is an inventor on patent application on AAV capsid variants(16/315,032). The author has no other competing interests to declare..
  18. William R Stauffer

    Neurobiology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    William R Stauffer, WRS in an inventor on a patent application for methods of AAV capsid development (PCT/US2019/068489). The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1031-8824
  19. Leah C Byrne

    University of Pittsburgh, Pittsburgh, PA, United States
    For correspondence
    lctbyrne@gmail.com
    Competing interests
    Leah C Byrne, LB is named as an inventor on patent applications on AAV capsid variants and AAV screening methods (U.S. Patent Applications No. 16/315,032, 16/486,681, PCT/US2019/068489). LB has consulted on AAV-mediated gene therapy for Vedere Therapeutics, and is a named founder of Vegavect and Newsight Therapeutics. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3229-4993

Funding

Ford Foundation

  • Leah C Byrne

UPMC Immune Transplant and Therapy Center

  • Leah C Byrne

Van Sloun Fund for Canine Genetic Research

  • Gustavo D Aguirre

National Eye Institute (F32EY023891)

  • Leah C Byrne

National Eye Institute (R24EY-022012)

  • David V Schaffer
  • John G Flannery
  • William A Beltran

National Eye Institute (R01EY017549)

  • Gustavo D Aguirre
  • William A Beltran

National Eye Institute (P30EY001583)

  • Gustavo D Aguirre
  • William A Beltran

National Institute of Mental Health (UG3MH120094)

  • Andreas R Pfenning
  • William A Beltran
  • Leah C Byrne

National Institute of Mental Health (DP2MH113095)

  • William R Stauffer

Research to Prevent Blindness

  • Leah C Byrne

Foundation Fighting Blindness

  • Leah C Byrne

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were performed in compliance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research, and for canine studies with approval by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC # 803813), and for the NHP and mouse studies with approval from the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC #18042326).

Copyright

© 2021, Öztürk et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,095
    views
  • 1,360
    downloads
  • 41
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bilge E Öztürk
  2. Molly E Johnson
  3. Michael Kleyman
  4. Serhan Turunç
  5. Jing He
  6. Sara Jabalameli
  7. Zhouhuan Xi
  8. Meike Visel
  9. Valérie L Dufour
  10. Simone Iwabe
  11. Felipe Pompeo Marinho
  12. Gustavo D Aguirre
  13. José-Alain Sahel
  14. David V Schaffer
  15. Andreas R Pfenning
  16. John G Flannery
  17. William A Beltran
  18. William R Stauffer
  19. Leah C Byrne
(2021)
scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution
eLife 10:e64175.
https://doi.org/10.7554/eLife.64175

Share this article

https://doi.org/10.7554/eLife.64175

Further reading

    1. Medicine
    Gabriel O Heckerman, Eileen Tzng ... Adrienne Mueller
    Research Article

    Background: Several fields have described low reproducibility of scientific research and poor accessibility in research reporting practices. Although previous reports have investigated accessible reporting practices that lead to reproducible research in other fields, to date, no study has explored the extent of accessible and reproducible research practices in cardiovascular science literature.

    Methods: To study accessibility and reproducibility in cardiovascular research reporting, we screened 639 randomly selected articles published in 2019 in three top cardiovascular science publications: Circulation, the European Heart Journal, and the Journal of the American College of Cardiology (JACC). Of those 639 articles, 393 were empirical research articles. We screened each paper for accessible and reproducible research practices using a set of accessibility criteria including protocol, materials, data, and analysis script availability, as well as accessibility of the publication itself. We also quantified the consistency of open research practices within and across cardiovascular study types and journal formats.

    Results: We identified that fewer than 2% of cardiovascular research publications provide sufficient resources (materials, methods, data, and analysis scripts) to fully reproduce their studies. Of the 639 articles screened, 393 were empirical research studies for which reproducibility could be assessed using our protocol, as opposed to commentaries or reviews. After calculating an accessibility score as a measure of the extent to which an article makes its resources available, we also showed that the level of accessibility varies across study types with a score of 0.08 for Case Studies or Case Series and 0.39 for Clinical Trials (p = 5.500E-5) and across journals (0.19 through 0.34, p = 1.230E-2). We further showed that there are significant differences in which study types share which resources.

    Conclusion: Although the degree to which reproducible reporting practices are present in publications varies significantly across journals and study types, current cardiovascular science reports frequently do not provide sufficient materials, protocols, data, or analysis information to reproduce a study. In the future, having higher standards of accessibility mandated by either journals or funding bodies will help increase the reproducibility of cardiovascular research.

    Funding: Authors Gabriel Heckerman, Arely Campos-Melendez, and Chisomaga Ekwueme were supported by an NIH R25 grant from the National Heart, Lung and Blood Institute (R25HL147666). Eileen Tzng was supported by an AHA Institutional Training Award fellowship (18UFEL33960207).

    1. Cell Biology
    2. Medicine
    Pengbo Chen, Bo Li ... Xinfeng Zheng
    Research Article

    Background:

    It has been reported that loss of PCBP2 led to increased reactive oxygen species (ROS) production and accelerated cell aging. Knockdown of PCBP2 in HCT116 cells leads to significant downregulation of fibroblast growth factor 2 (FGF2). Here, we tried to elucidate the intrinsic factors and potential mechanisms of bone marrow mesenchymal stromal cells (BMSCs) aging from the interactions among PCBP2, ROS, and FGF2.

    Methods:

    Unlabeled quantitative proteomics were performed to show differentially expressed proteins in the replicative senescent human bone marrow mesenchymal stromal cells (RS-hBMSCs). ROS and FGF2 were detected in the loss-and-gain cell function experiments of PCBP2. The functional recovery experiments were performed to verify whether PCBP2 regulates cell function through ROS/FGF2-dependent ways.

    Results:

    PCBP2 expression was significantly lower in P10-hBMSCs. Knocking down the expression of PCBP2 inhibited the proliferation while accentuated the apoptosis and cell arrest of RS-hBMSCs. PCBP2 silence could increase the production of ROS. On the contrary, overexpression of PCBP2 increased the viability of both P3-hBMSCs and P10-hBMSCs significantly. Meanwhile, overexpression of PCBP2 led to significantly reduced expression of FGF2. Overexpression of FGF2 significantly offset the effect of PCBP2 overexpression in P10-hBMSCs, leading to decreased cell proliferation, increased apoptosis, and reduced G0/G1 phase ratio of the cells.

    Conclusions:

    This study initially elucidates that PCBP2 as an intrinsic aging factor regulates the replicative senescence of hBMSCs through the ROS-FGF2 signaling axis.

    Funding:

    This study was supported by the National Natural Science Foundation of China (82172474).